It’s been a tough summer for the marijuana industry, with Horizons Medical Marijuana Life Sciences ETF falling 11.5% so far since June. Although the selloff in marijuana stocks as a whole has been pronounced, some have been hit harder than others, with CannTrust Holdings (TSX:TRST)(NYSE:CTST) down 57% year to date. Reasons given for the sector-wide selloff include disappointing earnings reports from major producers and increasing regulatory scrutiny on the industry.

If you are a buy-and-hold investor who thinks in decades, you need to look for a different type of company. That can mean looking past near-term losses to the long-term potential that a technology upstart like fast-growing Shopify (NYSE:SHOP) offers. Or the multiple ways that marijuana stock Canopy Growth (NYSE:CGC) has to reward investors willing to think long term. Or even examining a dividend growth story like the one offered by Hormel Foods (NYSE:HRL), which underpins over 50 years of success in the typically boring consumer goods space.

If you’d told someone two decades ago that recreational marijuana use would be legalized in Canada, they would not have believed you and would likely  have asked if you were high.

As of October 17, 2018, the Government of Canada legalized marijuana for recreational purposes.

Fast forward nine months, and Canada’s largest marijuana company Canopy Growth (TSX:WEED)(NYSE:CGC) has a market capitalization of almost $16 billion.

Canopy Growth’s stock price has increased 1,672% since its IPO, but this trend is unlikely to continue, and here is why.

CBD in Canada is not only popular, but the market is booming. According to a Bloomberg article, those in Canada can even get pot through the mail. It is also projected by BDS Analytics that sales may reach $4.7 billion by 2023.

Data by Statistics Canada also indicates that just this year, Canadians purchased $85 million worth of CBD from retail stores – and that is just in the month of May. It is also a 15 percent increase from sales in April.

Zenabis Global Inc. (ZENA.TO) ("Zenabis" or the "Company") is pleased to announce the licensing of Phase 2C – Part 1 at Zenabis Atholville (an additional 9,800 kg of licensed annual cultivation capacity).

Highlights:

At first glance, HEXO (TSX:HEXO)(NYSE:HEXO) seems like the rare value play in an overvalued sector. As of writing, the company has an enterprise value under a billion dollars, and based on management’s projections of a $400 million run rate for fiscal 2020, we are looking at a stock that is trading at just 2.3 times forward sales. But before you make a contrarian purchase here, consider these following factors.

The shares of CannTrust Holdings (TSX:TRST)(NYSE:CTST) are down 60.73% year to date. It’s hard to imagine the stock of a major cannabis player falling by this much when the sector’s organic growth is underway. CannTrust’s admission of wrongdoing this month is the latest disgrace to hit the cannabis space.

The scandal could hurt the marijuana industry. The cannabis producers are supposed to squeeze the black market. But CannTrust did the opposite and sold unlicensed cannabis. CannTrust has placed the marijuana industry in a tough spot. New legislative measures might be introduced and more regulatory probes conducted.

Though there are literally thousands of stocks for investors to choose from, it's a group of a few dozen in the budding marijuana industry that are garnering a lot of buzz. And it's not hard to see why, either. If investors had the foresight, fortitude, and luck to invest in some of the biggest cannabis stocks at the beginning of 2016, they'd be looking at quadruple-digit percentage gains today.

But there's more to investing in the marijuana industry than throwing a dart and hoping to get lucky. Here are 13 things you should know if you plan to invest in cannabis stocks.

As more Americans grow comfortable embracing the use of cannabis-related products, one company is hoping to bring a level of luxury to the marijuana culture.

That’s why celebrity jeweler Alex Todd founded Saucey Farms and Extracts. Launched in April 2019, the luxury cannabis brand sells premium products and organically grown strains of weed in California and Oregon, two states where recreational marijuana-use is legal. For Todd, it’s all about selling quality products.

Nasdaq-listed Israel-based cannabis company Therapix Biosciences Ltd. has signed a letter of intent for a proposed merger with Edmonton, Canada-based cannabis company Destiny Biosciences Global Corp., the former The merged company will focus on Therapix's technology and assets pertaining to clinical-stage pharmaceutical applications of cannabis, and will include Destiny's genomics-based cannabis breeding techniques and development capabilities, according to the company’s statement.

The companies expect a definitive agreement of the merger to be signed during the third quarter of 2019, subject to certain closing conditions. Upon closing, current Therapix equity holders are expected to own approximately 32% of the combined company, the company said.